ClinicalTrials.gg
CompletedNCT01973231LIRA-LIXI™Updated Feb 9, 2017Results posted

Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

A Phase 4 interventional study of liraglutide and lixisenatide in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 61 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-09.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
404
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
28th of 151
404 · median 62
Started
2013
with 17 others
Phase 4
48 of 151
1 open now
Registered
87th of 151
by date
Lead sponsor
63 of 151
Novo Nordisk A/S

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 28th largest by enrollment, is one of 18 that started in 2013, is one of 48 in phase 4, and was the 87th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of the trial is to investigate the efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in subjects with type 2 diabetes (T2DM).

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 404 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
  • Subjects diagnosed with T2DM and on unchanged metformin treatment at the maximum tolerated dose (at least 1000 mg/day and up to 3000 mg/day) for at least 90 days prior to screening
  • 7.5 - 10.5% (53 mmol/mol - 91 mmol/mol) (both inclusive)
  • (BMI) equal to or above 20 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Female of who is pregnant, breast-feeding or intend to become pregnant or is not using adequate methods. (Adequate contraceptive measures as required by local law or practice)
  • Treatment with glucose lowering agent(s) other than stated in the inclusion criteria in a period of 90 days prior to screening. Exception is short-term treatment (equal to or below 7 days in total) with insulin in connection with intercurrent illness
  • History of chronic pancreatitis or idiopathic acute pancreatitis
  • Screening calcitonin value equal to or above 50 ng/L
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)
  • Impaired liver function, defined as (ALAT) equal to or above 2.5 times upper normal limit (UNL)
  • Impaired renal function defined as estimated (eGFR) below 60 mL/min/1.73 m\^2 per Modification of Diet in Renal Disease (MDRD) formula
  • Any episode of unstable angina, acute coronary event, cerebral stroke/ (TIA) or other significant cardiovascular event as judged by the investigator within 90 days prior to screening
  • Heart failure, (NYHA) class IV
  • Uncontrolled hypertension (defined as systolic blood pressure equal to or above 180 mmHg and/or diastolic blood pressure equal to or above 100 mmHg)
  • Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
404 participants (actual)

Study arms

  • Experimental
    Metformin + liraglutide 1.8 mg

    Drug: liraglutide

  • Active comparator
    Metformin + lixisenatide 20 microg

    Drug: lixisenatide

Interventions

  • Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial metformin (equal to or above 1000 mg/day and up to 3000 mg/day).

  • Starting dose of 10 microg to be administered s.c. once daily, within the hour prior to the first meal of the day or the evening meal in addition to subject's stable pre-trial metformin (equal to or above 1000mg/day and up to 3000mg/day). Dose escalation to 20 microg s.c. once daily from day 15 after randomization.

07

What researchers measure

Primary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c) From Baseline

    Change from baseline in HbA1c after 26 weeks of treatment.

    Time frame: Week 0, week 26

Secondary outcomes

  1. Change in Fasting Plasma Glucose (FPG) From Baseline

    Change from baseline in FPG after 26 weeks of treatment.

    Time frame: Week 0, week 26

  2. Change in Body Weight From Baseline

    Change from baseline in body weight after 26 weeks of treatment.

    Time frame: Week 0, week 26

  3. Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) (American Diabetes Association (ADA) Target) (Yes/no)

    Subjects who achieved HbA1c below 7.0% (53 mmol/mol) after 26 weeks of treatment (yes/no).

    Time frame: After 26 weeks of treatment

  4. Subjects Who Achieve HbA1c Equal to or Below 6.5% (48 mmol/Mol) (American Association of Clinical Endocrinologists [AACE] Target) (Yes/no)

    Subjects who achieved HbA1c below equal to or below 6.5% (48 mmol/mol) after 26 weeks of treatment (yes/no).

    Time frame: After 26 weeks of treatment

  5. Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) and no Weight Gain (Yes/no)

    Subjects who achieved HbA1c below 7.0% (53 mmol/mol) and no weight gain after 26 weeks of treatment (yes/no).

    Time frame: After 26 weeks of treatment

  6. Number of Treatment Emergent Adverse Events (TEAEs)

    A Treatment Emergent Adverse Event (TEAE) was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. Severity was assessed by investigator.

    Time frame: Weeks 0-26

08

Results

Posted Dec 22, 2015

Participant flow

The trial was conducted at 56 sites in 9 countries; Czech Republic (5), Finland (4), France (6), Germany (8), Hungary (6), Italy (5), Latvia (6), Lithuania (5) and UK (11).

Participant flow — Overall Study
MilestoneLiraglutideLixisenatide
Started202202
Completed191190
Not completed1112
Withdrew: Protocol violation11
Withdrew: Lost to follow-up11
Withdrew: Unclassified21
Withdrew: Withdrawal by subject79

Outcome measures

PrimaryChange in Glycosylated Haemoglobin (HbA1c) From Baseline

Change from baseline in HbA1c after 26 weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · Percent (%) glycosylated haemoglobin
Change in Glycosylated Haemoglobin (HbA1c) From Baseline
Percent (%) glycosylated haemoglobinLiraglutideLixisenatide
Change in Glycosylated Haemoglobin (HbA1c) From Baseline-1.809 ± 0.9159-1.238 ± 1.0085
SecondaryChange in Fasting Plasma Glucose (FPG) From Baseline

Change from baseline in FPG after 26 weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change in Fasting Plasma Glucose (FPG) From Baseline
mmol/LLiraglutideLixisenatide
Change in Fasting Plasma Glucose (FPG) From Baseline-2.904 ± 2.2309-1.644 ± 2.1511
SecondaryChange in Body Weight From Baseline

Change from baseline in body weight after 26 weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · kg
Change in Body Weight From Baseline
kgLiraglutideLixisenatide
Change in Body Weight From Baseline-4.24 ± 4.273-3.69 ± 4.746
SecondarySubjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) (American Diabetes Association (ADA) Target) (Yes/no)

Subjects who achieved HbA1c below 7.0% (53 mmol/mol) after 26 weeks of treatment (yes/no).

Time frame:
After 26 weeks of treatment
Reported as:
Number · percentage (%) of subjects
Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) (American Diabetes Association (ADA) Target) (Yes/no)
percentage (%) of subjectsLiraglutideLixisenatide
Yes74.245.5
No25.854.5
SecondarySubjects Who Achieve HbA1c Equal to or Below 6.5% (48 mmol/Mol) (American Association of Clinical Endocrinologists [AACE] Target) (Yes/no)

Subjects who achieved HbA1c below equal to or below 6.5% (48 mmol/mol) after 26 weeks of treatment (yes/no).

Time frame:
After 26 weeks of treatment
Reported as:
Number · percentage (%) of subjects
Subjects Who Achieve HbA1c Equal to or Below 6.5% (48 mmol/Mol) (American Association of Clinical Endocrinologists [AACE] Target) (Yes/no)
percentage (%) of subjectsLiraglutideLixisenatide
Yes54.626.2
No45.473.8
SecondarySubjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) and no Weight Gain (Yes/no)

Subjects who achieved HbA1c below 7.0% (53 mmol/mol) and no weight gain after 26 weeks of treatment (yes/no).

Time frame:
After 26 weeks of treatment
Reported as:
Number · percentage (%) of subjects
Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) and no Weight Gain (Yes/no)
percentage (%) of subjectsLiraglutideLixisenatide
Yes66.541.9
No33.558.1
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs)

A Treatment Emergent Adverse Event (TEAE) was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. Severity was assessed by investigator.

Time frame:
Weeks 0-26
Reported as:
Number · events
Number of Treatment Emergent Adverse Events (TEAEs)
eventsLiraglutideLixisenatide
Events540435
Serious137
Severe103
Moderate10984
Mild421348

Adverse events

Collected over Weeks 0-26. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liraglutide—12/202 (5.9%)90/202 (44.6%)
Lixisenatide—7/202 (3.5%)83/202 (41.1%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventLiraglutideLixisenatide
Atrial fibrillationCardiac disorders0/2021/202
Cardiac failureCardiac disorders0/2021/202
Coronary artery diseaseCardiac disorders0/2021/202
Myocardial ischaemiaCardiac disorders1/2020/202
Abdominal herniaGastrointestinal disorders1/2020/202
Gastric ulcer haemorrhageGastrointestinal disorders1/2020/202
Oesophageal ulcer haemorrhageGastrointestinal disorders1/2020/202
PyrexiaGeneral disorders1/2020/202
Cholecystitis acuteHepatobiliary disorders1/2020/202
Diabetic foot infectionInfections and infestations1/2020/202
Most frequent other events
Most frequent other events
EventLiraglutideLixisenatide
NauseaGastrointestinal disorders44/20244/202
DiarrhoeaGastrointestinal disorders25/20220/202
NasopharyngitisInfections and infestations13/20220/202
VomitingGastrointestinal disorders14/20218/202
Lipase increasedInvestigations17/2025/202
HeadacheNervous system disorders15/20217/202
Decreased appetiteMetabolism and nutrition disorders13/2025/202
DyspepsiaGastrointestinal disorders11/2026/202

Baseline characteristics

Age, Continuous
Age, Continuous(years)LiraglutideLixisenatideTotal
Mean56.3 ± 10.656.1 ± 10.056.2 ± 10.3
Gender
Gender(Participants)LiraglutideLixisenatideTotal
Female7090160
Male132112244
Glycosylated Haemoglobin (HbA1c)
Glycosylated Haemoglobin (HbA1c)(Percent (%) glycosylated haemoglobin)LiraglutideLixisenatideTotal
Mean8.40 ± 0.7238.43 ± 0.7858.41 ± 0.754
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)LiraglutideLixisenatideTotal
Mean10.47 ± 2.36810.25 ± 2.25410.36 ± 2.312
Body Weight
Body Weight(kg)LiraglutideLixisenatideTotal
Mean101.89 ± 23.344100.58 ± 19.949101.24 ± 21.696
09

Study locations

61 sites
  • Novo Nordisk Investigational Site
    Hradec Kralove, 50005, Czech Republic
  • Novo Nordisk Investigational Site
    Mlada Boleslav, 293 50, Czech Republic
  • Novo Nordisk Investigational Site
    Olomouc, 77900, Czech Republic
  • Novo Nordisk Investigational Site
    Plzen, 32600, Czech Republic
  • Novo Nordisk Investigational Site
    Prostejov, 79601, Czech Republic
  • Novo Nordisk Investigational Site
    Helsinki, 00260, Finland
  • Novo Nordisk Investigational Site
    Jyväskylä, 40100, Finland
  • Novo Nordisk Investigational Site
    Oulu, FI-90220, Finland
  • Novo Nordisk Investigational Site
    Pori, FI-28120, Finland
  • Novo Nordisk Investigational Site
    Rovaniemi, 96400, Finland
  • Novo Nordisk Investigational Site
    Boulogne Billancourt, 92100, France
  • Novo Nordisk Investigational Site
    Corbeil Essonnes, 91106, France
  • Novo Nordisk Investigational Site
    Hinx, 40180, France
  • Novo Nordisk Investigational Site
    LA ROCHELLE cedex, 17019, France
  • Novo Nordisk Investigational Site
    Saint Herblain, 44800, France
  • Novo Nordisk Investigational Site
    Strasbourg, 67000, France
  • Novo Nordisk Investigational Site
    Venissieux, 69200, France
  • Novo Nordisk Investigational Site
    Bad Lauterberg, 37431, Germany
  • Novo Nordisk Investigational Site
    Berlin, 13055, Germany
  • Novo Nordisk Investigational Site
    Bochum, 44869, Germany
  • Novo Nordisk Investigational Site
    Dresden, 01219, Germany
  • Novo Nordisk Investigational Site
    Duisburg, 47051, Germany
  • Novo Nordisk Investigational Site
    Friedrichsthal, 66299, Germany
  • Novo Nordisk Investigational Site
    Lampertheim, 68623, Germany
  • Novo Nordisk Investigational Site
    Ludwigshafen, 67059, Germany
  • Novo Nordisk Investigational Site
    St. Ingbert, 66386, Germany
  • Novo Nordisk Investigational Site
    Baja, 6500, Hungary
  • Novo Nordisk Investigational Site
    Budapest, 1042, Hungary
  • Novo Nordisk Investigational Site
    Budapest, 1089, Hungary
  • Novo Nordisk Investigational Site
    Budapest, 1125, Hungary
  • Novo Nordisk Investigational Site
    Gyula, 5700, Hungary
  • Novo Nordisk Investigational Site
    Pécs, 7623, Hungary
  • Novo Nordisk Investigational Site
    Salgótarján, 3100, Hungary
  • Novo Nordisk Investigational Site
    Szeged, H-6720, Hungary
  • Novo Nordisk Investigational Site
    Catania, 95122, Italy
  • Novo Nordisk Investigational Site
    Cittadella (PD), 35013, Italy
  • Novo Nordisk Investigational Site
    Padova, 35143, Italy
  • Novo Nordisk Investigational Site
    Palermo, 90129, Italy
  • Novo Nordisk Investigational Site
    Terni, 05100, Italy
  • Novo Nordisk Investigational Site
    Ogre, LV-5001, Latvia
  • Novo Nordisk Investigational Site
    Riga, LV-1002, Latvia
  • Novo Nordisk Investigational Site
    Riga, LV-1012, Latvia
  • Novo Nordisk Investigational Site
    Riga, LV-1024, Latvia
  • Novo Nordisk Investigational Site
    Riga, LV-1038, Latvia
  • Novo Nordisk Investigational Site
    Kaunas, 48259, Lithuania
  • Novo Nordisk Investigational Site
    Kaunas, 50009, Lithuania
  • Novo Nordisk Investigational Site
    Klaipeda, 94198, Lithuania
  • Novo Nordisk Investigational Site
    Siauliai, 76231, Lithuania
  • Novo Nordisk Investigational Site
    Vilnius, 08661, Lithuania
  • Novo Nordisk Investigational Site
    Basingstoke, RG24 9GT, United Kingdom
  • Novo Nordisk Investigational Site
    Bristol, BS10 5NB, United Kingdom
  • Novo Nordisk Investigational Site
    Chester, CH2 1UL, United Kingdom
  • Novo Nordisk Investigational Site
    Chiswick, W4 3JL, United Kingdom
  • Novo Nordisk Investigational Site
    Coventry, CV2 2DX, United Kingdom
  • Novo Nordisk Investigational Site
    Derby, DE22 3NE, United Kingdom
  • Novo Nordisk Investigational Site
    Devon, EX2 5DW, United Kingdom
  • Novo Nordisk Investigational Site
    Great Yarmouth, NR31 6LA, United Kingdom
  • Novo Nordisk Investigational Site
    Lancaster, LA1 1RP, United Kingdom
  • Novo Nordisk Investigational Site
    Plymouth, PL6 8BQ, United Kingdom
  • Novo Nordisk Investigational Site
    Sandbach, CW11 1EQ, United Kingdom
  • Novo Nordisk Investigational Site
    Taunton, TA1 5DA, United Kingdom
10

References and documents

Publications

  • Nauck M, Rizzo M, Johnson A, Bosch-Traberg H, Madsen J, Cariou B. Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. Diabetes Care. 2016 Sep;39(9):1501-9. doi: 10.2337/dc15-2479. Epub 2016 Jun 16. PubMed 27311491 ↗
  • Hunt B, Vega-Hernandez G, Valentine WJ, Kragh N. Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting. Diabetes Obes Metab. 2017 Jun;19(6):842-849. doi: 10.1111/dom.12890. Epub 2017 Feb 23. PubMed 28124820 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2013
First posted
Oct 31, 2013
Start
Oct 2013
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results first posted
Dec 22, 2015
Last update
Feb 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01973231
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 31, 2013
Start date
Oct 2013
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Dec 22, 2015
Last update
Feb 9, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion